Single agent Taxol for relapsed small cell lung cancer – pro
Small cell lung cancer that progresses after first line chemotherapy has a poor prognosis. A variety of treatments are available, among them single agent Taxol.The literature contains studies in various schedules, including weekly and dose-dense, as well as various combination therapies. Single agent Taxol is also listed for sequential use by NCCN. However, combination regimesn with Taxol have some phase II data, but are not supported by guidelines, such as NCCN and others.
Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M. II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.Anticancer Res. 2006 Jan-Feb;26(1B):777-81.
Graziano SL, Herndon JE 2nd, Socinski MA, Wang X, Watson D, Vokes E, Green MR; Cancer and Leukemia Group B.Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.Thorac Oncol. 2008 Feb;3(2):158-62.
nccn.org, small cell lung cancer, 2103